meta|Evidence - COVID-19
click on circles to display study description...
fluvoxamine (n=80) vs. placebo (n=72)
randomized controlled trial some concerns about risk of bias
fluvoxamine
100mg 3 times daily for 15 days
placebo
COVID 19 outpatients
double-blind
St Louis metropolitan area (Missouri and Illinois), USA
fluvoxamine (n=334) vs. placebo (n=327)
randomized controlled trial some concerns about risk of bias
fluvoxamine at a dose of 50 mg twice daily for 14 days
placebo
COVID 19 outpatients
double-blind
US, 6 centres
2-by-3 factorial design (metformin, ivermectin, and fluvoxamine)
fluvoxamine (n=741) vs. placebo (n=756)
randomized controlled trial some concerns about risk of bias
Fluvoxamine
100mg twice daily for 10 days.
Placebo
Twice daily for 10 days.
All participants received usual standard care for COVID-19 provided by healthcare professionals workers at public health facilities. Clinicians providing usual care in public health facilities typically focus on the management of symptoms and with antipyretics, and recommend antibiotics only if they suspect bacterial pneumonia.
COVID 19 outpatients
Patients over 18 years old with the ability to provide free and informed consent with Acute Flu-Like symptoms < 07 days and at least ONE enhancement criteria (Age > 50 years; Diabetes mellitus requiring oral medication or insulin Systemic arterial hypertension requiring at least 01 oral medication for BP control; Known cardiovascular diseases (heart failure, congenital heart disease, valvar heart valve disease, coronary artery disease, cardiomyopathies) Symptomatic lung disease (emphysema, chronic bronchitis) Symptomatic asthma patients requiring chronic use of agents for control of symptoms. Fever > 38 C at baseline Obesity, defined as BMI> 30 kg / m2 body weight Transplanted patients Patient with stage IV chronic kidney disease or on dialysis. Immunosuppressed patients/ using corticosteroid therapy (equivalent to maximum 10 mg of prednisone per day) and/ or immunosuppressive therapy) Patients with a history of cancer in the last 05 years or undergoing treatment of a current cancer Chronic renal disease KDIGO IV or End-Stage Renal Disease on chronic ambulatory renal replacement therapy Patients with important limitation of daily activities due to: Dyspnea, chest pain myalgia (limited to 25% of all randomizations) ). Patient with positive rapid test for SARS-CoV2 antigen performed on occasion of the screening or patient with a positive SARS-CoV2 diagnostic test within 07 days of the onset of symptoms.
Double-blind.
10 sites in Minas Gerais, Brazil.
Bayesian analysis.
Some inconsistencies between preprint and publication in terms of population size and inclusion period.
fluvoxamine (n=674) vs. placebo (n=614)
randomized controlled trial low risk of bias
fluvoxamine
fluvoxamine 50 mg twice daily for 10 days
placebo
COVID 19 outpatients
non-hospitalized adults aged ≥30 years with confirmed COVID-19 experiencing ≥2 symptoms of acute infection for ≤7 days prior to randomization
double-blind
time to sustained recovery was defined as the third of 3 consecutive days without symptoms
powered by vis.js Network